stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Total debt
Takeda Pharmaceutical Co.'s total debt at the end of fiscal 2026 was $32.2B, up 8.12% from $29.8B in fiscal 2025. At the end of the quarter to 30 September 2026 it was $28.8B. Over the past ten years it has ranged from $6.4B (fiscal 2016) to $51.8B (fiscal 2019); the current reading is higher than 50% of that period. Takeda Pharmaceutical Co. ranks 1st of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2026 | $32.2B | 8.12% |
| FY2025 | $29.8B | (10.83%) |
| FY2024 | $33.4B | 3.06% |
| FY2023 | $32.4B | (16.15%) |
| FY2022 | $38.7B | (11.24%) |
| FY2021 | $43.6B | (7.01%) |
| FY2020 | $46.9B | (9.47%) |
| FY2019 | $51.8B | 483.46% |
| FY2018 | $8.9B | (16.68%) |
| FY2017 | $10.6B | 66.99% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $28.8B | (7.37%) |
| Jun 2026 | $31.1B | (1.35%) |
| Dec 2025 | $31.5B | (0.13%) |
| Sep 2025 | $31.6B | 1.60% |
| 30 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TAK Takeda Pharmaceutical Co. | $28.8B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $16.7B |
| HLN Haleon PLC Sponsored ADR compare | $11.1B |
| ZTS Zoetis Inc. compare | $9.0B |
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| VTRS Viatris Inc. compare | $1.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $274.0M |
| UTHR United Therapeutics Corporation compare | $200.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement